EUVIMEDEUVIMED entdecken
Open Access

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia

Qi Jin iD, Ethan Harris iD, Jacquelyn A Myers iD, Rashid Mehmood iD, Anitria Cotton, Hazheen K Shirnekhi, David W Baggett, Jeremy Qiang Wen, Andrew B Schild iD, Rahul S Bhansali iD, Jonathon Klein, Shilpa Narina iD und 9 weitere

Blood · 2024

DOI: 10.1182/blood.2024024281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Qi Jin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Precursor Cell Lymphoblastic Leukemia-Lymphoma, RNA Splicing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are only a few options for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), thus, this is a major area of unmet medical need. In this study, we reveal that the inclusion of a poison exon in RBM39, which could be induced by both CDK9 or CDK9 independent cyclin-dependent kinases, mitogen-activated protein kinases, glycogen synthase kinases, CDC-like kinases (CMGC) kinase inhibition, is recognized by the nonsense-mediated messenger RNA decay pathway for degradation. Targeting this poison exon in RBM39 with CMGC inhibitors led to protein downregulation and the inhibition of ALL growth, particularly in relapsed/refractory B-ALL. Mechanistically, disruption of cotranscriptional splicing by the inhibition of CMGC kinases, including DYRK1A, or inhibition of CDK9, which phosphorylate the C-terminal domain of RNA polymerase II (Pol II), led to alteration in the SF3B1 and Pol II association. Disruption of SF3B1 and the transcriptional elongation complex altered Pol II pausing, which promoted the inclusion of a poison exon in RBM39. Moreover, RBM39 ablation suppressed the growth of human B-ALL, and targeting RBM39 with sulfonamides, which degrade RBM39 protein, showed strong antitumor activity in preclinical models. Our data reveal that relapsed/refractory B-ALL is susceptible to pharmacologic and genetic inhibition of RBM39 and provide 2 potential strategies to target this axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsPrecursor Cell Lymphoblastic Leukemia-LymphomaRNA SplicingHumansAnimalsMiceCell Line, TumorCyclin-Dependent Kinase 9ExonsRNA Polymerase IIXenograft Model Antitumor AssaysNonsense Mediated mRNA Decay

Substanzen

RNA-Binding ProteinsCyclin-Dependent Kinase 9RNA Polymerase II

Autor:innen und Institutionen

  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Medicine, The University of Chicago, Chicago, IL.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN.
  • Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Center for Advanced Genome Engineering and the Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN.

ORCID-Profile: Qi Jin, Ethan Harris, Jacquelyn A Myers, Rashid Mehmood, Andrew B Schild, Rahul S Bhansali, Shilpa Narina, Shondra M Pruett-Miller, Sebastien Malinge, Esther A Obeng, John D Crispino

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS

Zitieren

APA

Jin, Q., Harris, E., Myers, J. A., Mehmood, R., Cotton, A., Shirnekhi, H. K., Baggett, D. W., Wen, J. Q., Schild, A. B., Bhansali, R. S., Klein, J., Narina, S., Pieters, T., Yoshimi, A., Pruett-Miller, S. M., Kriwacki, R., Abdel-Wahab, O., Malinge, S., Ntziachristos, P., …, & Crispino, J. D. (2024). Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood.2024024281

Vancouver

Jin Q, Harris E, Myers JA, Mehmood R, Cotton A, Shirnekhi HK, et al. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood. 2024. doi:10.1182/blood.2024024281

BibTeX
@article{Jin2024,
  author = {Jin, Qi and Harris, Ethan and Myers, Jacquelyn A and Mehmood, Rashid and Cotton, Anitria and Shirnekhi, Hazheen K and Baggett, David W and Wen, Jeremy Qiang and Schild, Andrew B and Bhansali, Rahul S and Klein, Jonathon and Narina, Shilpa and Pieters, Tim and Yoshimi, Akihide and Pruett-Miller, Shondra M and Kriwacki, Richard and Abdel-Wahab, Omar and Malinge, Sebastien and Ntziachristos, Panagiotis and Obeng, Esther A and Crispino, John D},
  title = {Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2024024281}
}
Kostenlos starten →